­A MULTIVALENT PROTEIN-BASED VACCINE CANDIDATES DISPLAYING SARS-COV-2 SPIKE VARIANTS FOR ELICITATION OF NEUTRALIZING AND PROTECTIVE ANTIBODIES AGAINST INFECTION

A MULTIVALENT PROTEIN-BASED VACCINE CANDIDATES DISPLAYING SARS-COV-2 SPIKE VARIANTS FOR ELICITATION OF NEUTRALIZING AND PROTECTIVE ANTIBODIES AGAINST INFECTION

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes COVID-19, a respiratory illness. SARS-CoV-2 has spread throughout the world and has already resulted in over 16 million cases of COVID-19 and over 600 thousand deaths. SARS-CoV-2 is highly infectious and primarily spreads between people through close contact and respiratory droplets. Long-term control of SARS-CoV-2 will require an effective vaccine that can be made widely available across the globe.

Stage of Research

Researchers have utilized a multivalent nanoparticle platform to create a protein-based vaccine candidate against the trimeric viral Spike protein of SARS-CoV-2. Specifically, the vaccine is composed of residues of the Spike protein and Helicobacter pylori ferritin combined by a linker. Mice immunized with this candidate produced a strong neutralizing antibody response as compared to mice immunized with other variations of the Spike receptor binding domain, full length Spike soluble trimers and other vaccine components. The neutralizing antibody response was seen as early as 21 days after immunization.

Applications

  • This vaccine could be used as an alternative to the existing vaccines that have been approved.
  • This vaccine could be used to inform the development and characterization of other subunit vaccines against SARS-CoV-2.

Stage of Development

Proof of concept with in vitro and in vivo data

Publications

Published (ACS Cent. Sci. 2021, 7, 1, 183–199)

PCT application publication WO2021231481

Related Web Links

https://peterkimlab.stanford.edu/

Keywords

COVID-19, vaccine, SARS-CoV-2, nanoparticle

Technology Reference

CZB-176S, Stanford S20-289

Patent Information:
For Information, Contact:
Maureen Sheehy
General Counsel
CZ Biohub
ip@czbiohub.org
Inventors:
Abigail Powell
Peter Kim
Keywords:
COVID-19
Nanoparticle
SARS-CoV-2
Vaccine